Endo to cut 560 staffers, shutter drug plants to save cash for spring cellulite launch

Endo to cut 560 staffers, shutter drug plants to save cash for spring cellulite launch

Source: 
Fierce Pharma
News Tags: 
snippet: 

After several tough years and a CEO switch earlier in 2020, Endo is overhauling its operations—and cutting hundreds of jobs—to better position itself for a drug launch next spring.

The company on Thursday unveiled a move to cut 560 positions by the first half of 2026 to save $85 million to $95 million annually. Meanwhile, it will exit manufacturing facilities in California and New York and jettison an active pharmaceutical ingredient site in India.